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Introduction
The incretin hormone, GIP, is responsible for augment-
ing postprandial insulin release and regulation of b-cell
mass. The advent of newly-developed GIP analogues,
which have been demonstrated to restore glycaemic con-
trol in animal models of type 2 diabetes mellitus
(T2DM), suggest that GIP-based therapies may now rea-
lise their long-held promise for the treatment of T2DM.
Interestingly, we have recently shown that GIP may also
exert vasodilatory actions which appear to be mediated
via endothelium-dependent NO production. This may be
particularly relevant to T2DM as over 60 % of associated
mortality is attributable to cardiovascular disease related
to dysregulation of endothelial NO homeostasis. An
improved understanding of the mechanisms underlying
GIP’s recently-described vascular actions is clearly
important. The aim of this study was therefore to dissect
the precise mechanisms involved in GIP-mediated
endothelial NO signalling.
Methods
Bovine aortic endothelial cells (BAECs) were isolated and
cultured to confluence. Immunofluorescence microscopy
was used to confirm the purity and identity of the BAEC
preparation. Cells were then treated with GIP (0.1 µM) for
24 hours in the presence or absence of specific inhibitors
of candidate signalling pathways before NO production
was assessed using the Greiss assay.
Results
GIP was found to induce marked NO production in
BAECs (control, 62.3±17.3 µM vs GIP, 32.3±6.3 µM ;
P<0.001, n=9 ), which was significantly attenuated by the
GIP receptor antagonist Pro3-GIP (32.3±6.3 µM; P<0.01,
n=3), the Ca2+-calmodulin inhibitor KN-93 (32.3±6.3
µM; P<0.05, n=3) and the PI3K inhibitor wortmannin
(32.3±6.3 µM; P<0.05, n=2). However, GIP-induced NO
production was unaffected by either the Gs activator,
cholera toxin, the adenylate cyclase inhibitor, MDL-
12,330A or the adenylate cyclase activator, forskolin
(P>0.05, n=2). Data presented as mean ±SEM.
Conclusions
GIP directly stimulates NO production in BAEC’s via a
mechanism involving the GIP receptor, PI3K, and Ca2+-
dependent eNOS activation. These actions may be related
to GS activation, although its precise link to this pathway
remains unclear. Further research into the precise role of
GIP in the vasculature may allow for the future develop-
ment of novel GIP-based treatments in T2DM with addi-
tional cardiovascular benefits beyond those relating to
glycaemic control.
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